| 52 Week Rng | - |
| Market Cap | - |
| Avg Volume | - |
| 1M Volatility | - |
| Short Ratio | - |
| P/E Ratio (TTM) | - |
| P/E Ratio (Fwd) | - |
| P/B Ratio | - |
| Div & Yield | - |
Group91 • Aalto Investment Management Game (Fall 2020) • 1w
Quality Strategy I Rebalancing each stock sector wise to match our benchmark index, according to the investment strategy
KTOCapital • Aalto Investment Management Game (Fall 2020) • 3w
Passive Buy-Hold Strategy, Long Position, Healthcare industry, fast growth stock, higher risk and higher profit potential
Alpha_Partners • Aalto Investment Management Game (Fall 2020) • 3w
Long momentum strategy │equal weighting │ long leg: 17 stocks with highest returns over past 52-weeks │ Market Cap over 1B USD
finance_boys_sauna_evening • Aalto Investment Management Game (Fall 2020) • 3w
Momentum strategy | Equal weighting | 25 stocks with high expected returns in November
AIJOFund • Aalto Investment Management Game (Fall 2020) • 3w
Momentum strategy | Equal weighting | Long position: 30 stocks with highest cumulative returns during the last 12 months | Rank 16
*Includes only companies available in the game
NERDYPANTS96 • Stockfuse Continuum (US) • Sep 2020
In mid august, QDEL and BDX were the only healthcare companies to receive federal emergency authorization from the FDA for COVID-19 antigen tests. This caused a buzz and resulted in QDEL's stock to be temporarily overpriced. It probably is still overpriced. This would not be a wise long term investment as more medical companies have been given the authorization to use the new test and a vaccine would decrease the amount of testing needed anyway. Most of their growth has been due to COVID but their revenue is less reliant on COVID when compared to BDX. This is a good short term investment because the situation in the US surrounding COVID is awful and I don't expect it to get better anytime soon.
r.liceti • Stockfuse Continuum (US) • Sep 2020
Strong COVID stock. Outperformed estimates on EPS the last 4 quarters. Drastic drop some days ago, still even the lowest forecasts predict massive increases in EPS.